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Abstract
Background: Enteroviruses are among the most common viruses infecting humans worldwide and they
are associated with diverse clinical syndromes. Acute flaccid paralysis (AFP) is a clinical manifestation of
enteroviral neuropathy, transverse myelitis, Guillian-Barre Syndrome, Traumatic neuritis and many other
nervous system disorders. The objective of this study was to understand the role of Non-Polio
Enteroviruses (NPEV) towards this crippling disorder.
Methods: Stool specimens of 1775 children, aged less than 15 years, suffering from acute flaccid paralysis
were collected after informed consent within 14 days of onset of symptoms during January 2003 to
September 2003. The specimens were inoculated on RD and L20B cells using conventional tube cell
culture while micro-neutralization test was used to identify the non-polio enterovirus (NPEV) serotypes.
Detailed clinical information and 60-days follow-up reports were analyzed for NPEV-associated AFP cases.
Results: NPEV were isolated from 474 samples. The male to female ratio was 1.4:1. The isolation of NPEV
decreased significantly with the increase in age. Cases associated with fever at the onset of NPEV-
associated AFP were found to be 62%. The paralysis was found asymmetrical in 67% cases, the progression
of paralysis to peak within 4 days was found in 72% cases and residual paralysis after 60 days of paralysis
onset was observed in 39% cases associated with NPEV. A clinical diagnosis of Guillian-Barre syndrome
was made in 32% cases. On Microneutralization assay, echo-6 (13%) and coxsackievirus B (13%) were the
most commonly isolated serotypes of NPEV along with E-7, E-13, E-11, E-4 and E-30. The isolates (n =
181) found untypable by the antiserum pools were confirmed as NPEV by PCR using Pan-Enterovirus
primers.
Conclusion: The present study suggests that NPEV are a dominant cause of AFP and different serotypes
of NPEV are randomly distributed in Pakistan. The untypable isolates need further characterization and
analysis in order to determine their association with clinical presentation of a case.
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Background
Enteroviruses (genus Enterovirus, family Picornaviridae)
are among the most common viruses infecting humans
worldwide. Enteroviruses are associated with diverse clin-
ical syndromes ranging from minor febrile illness to
severe, potentially fatal conditions (e.g., aseptic meningi-
tis, encephalitis, paralysis, myocarditis, and neonatal
enteroviral sepsis) and could be linked with the develop-
ment of some chronic diseases (e.g., type 1 diabetes and
dilated cardiomyopathy) [1,2].
Serotypes of human enteroviruses have traditionally been
classified into echoviruses, coxsackieviruses group A and
B, and polioviruses. This traditional taxonomy was based
on the associated disease in humans and animal model
systems, sometimes resulting in overlaps between groups
and difficulties with classification. As a result, beginning
in the 1960s, newly discovered enteroviruses received a
numeric designation (e.g., enterovirus 71) instead of
being assigned to one of the traditional groups [1].
Current taxonomy takes into account molecular and bio-
logic characteristics and divides human enteroviruses into
four species (human enterovirus [HEV] A, B, C, and D)
but keeps traditional names for individual serotypes [3].
Sixty-eight serotypes are included in the International
Committee on Taxonomy of Viruses classification. The
distribution of enteroviruses by species only partially cor-
responds to the groups in the traditional classification.
Because molecular techniques of enterovirus typing are
becoming increasingly available, new enteroviruses con-
tinue to be identified, and enteroviruses 79–101 have
been recently described [4-12]. Echoviruses 22 and 23
have been reclassified as a new genus (Parechovirus) in
Picornaviridae and are termed human parechoviruses 1
and 2, respectively. Although they belong to genetically
and biologically distinct genera, human parechoviruses
and human enteroviruses share many epidemiologic and
clinical characteristics [3].
Various studies in India suggest the frequency of NPEV
isolation from acute flaccid paralysis (AFP) cases from
20% to 54% [13-15]. Most of the AFP cases in United
States of America were found to be caused by NPEV in the
post vaccination era [16]. Several cases of paralysis were
reported in association with enteroviruses, especially cox-
sackieviruses in Scotland [17]. Paralysis has also been
reported in association with coxsackieviruses B2-B6,
enterovirus 71 and echovirus types 3, 4, 6, 9, 11, 19 and
22 [18-20].
Enteroviruses grow well on HeLa cells, Hep-2 cells,
human rhabdomyosarcoma cell line RD cells, MRC-5
cells, human embryonic kidney cells and buffalo green
monkey kidney cells [21] but the RD cell line was found
to be the most sensitive cell line for the isolation of enter-
oviruses [22]. Enteroviruses can be isolated from faeces,
pharyngeal washings, cerebrospinal fluid (CSF), spinal
cord, brain, heart, blood, conjunctivae and lesions of skin
or mucous membrane. Retrospective evaluation of the rel-
ative utilities of different clinical specimens has proven
that stool should be cultured for all patients suspected of
NPEV infection [23].
Serotypes may be identified by reference antisera. The
antiserum pools are issued in freeze-dried form to refer-
ence centres after formal request to WHO, Geneva [24].
The main objective to conduct this study was to identify
the NPEV serotypes prevalent in Pakistan and their associ-
ation with AFP cases.
Methods
a) Patients and specimens
The study was approved by Internal Review Board of
National Institute of Health, Islamabad. All AFP cases in
children aged <15 years were detected through active sur-
veillance with a network of surveillance officers posted
through out the country during January 2003 to Septem-
ber 2003. Two stool samples 24–48 hours apart from a
total of 1775 AFP cases were collected within 14 days of
onset of paralysis with the prior oral/verbal informed con-
sent. Patient information was recorded on a standard
questionnaire including demographic details, date of
onset of paralysis and clinical presentation like fever at the
onset of paralysis, symmetry of paralysis, location of
paralysis and time duration for paralysis progression to
peak. Specimens were transported to the Regional Refer-
ence Laboratory, National Institute of Health, Islamabad
in good condition (cold chain maintained, container not
leaking, good specimen quality and adequate quantity).
Sixty-day follow-up reports were obtained through the
same network.
b)Virus isolation
The samples were treated with chloroform to remove bac-
teria and fungi and to dissociate virus aggregates. Conven-
tional tube cell culture method was used for virus
isolation in accordance with WHO recommendations
[25,26]. Each specimen extract (0.2 ml) was inoculated in
two cell culture tubes, one containing RD cells and other
L20B cells, after aspirating the growth medium and
replacing it with 1 ml maintenance medium. The tubes
were incubated in the stationary sloped (5°) position at
36°C and examined daily for evidence of cytopathic effect
(CPE). When complete CPE was obtained, the infected
cells were harvested and kept frozen (-20°C) until typing.
c) Microneutralization assay
The typing sera kit was provided by the National Institute
of Public Health and the Environment, Bilthoven, theBMC Infectious Diseases 2007, 7:6 http://www.biomedcentral.com/1471-2334/7/6
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Netherlands (RIVM). The kit contained reference-typing
sera against 21 of the 64 known human NPEV serotypes
combined as nine antiserum pools. 50 μl of antisera was
added to the appropriate wells of microtiter plate. Each
isolate was tested in duplicate against all the NPEV antise-
rum pools using 10-3 and 10-4dilutions. 50 μl of both the
dilutions were dropped in respective wells and incubated
at 37°C for one hour. After incubation, 100 μl of RD cell
suspension was distributed into these wells and the plates
were incubated at 37°C after covering with non-toxic
sealer. Virus controls and cell controls were run along for
comparison. The plates were examined daily, till the virus
control showed 4+ CPE. The identification was made by
analyzing the pattern of inhibition of CPE by the antise-
rum pools.
d) Polymerase chain reaction
In vitro amplification of the virus isolates was performed
by PCR using pan-Enterovirus (Pan-EV) primers which
were found untypable by neutralization test. The primer
sequence was as follow
5'-ACACGGACACCCAAAGTAGTCGGTTCC-3'
5'-TCCGGCCCCTGAATGCGGCTAATCC-3'
The primers used for PCR amplification were selected
from the highly conserved 5'non-coding region of the
enterovirus and product was amplified by one step RT/
PCR [27]. Non-infectious control RNA of pan-enterovi-
ruses was used as positive control, culture supernatant
from uninfected cells was used as negative control while
buffer instead of samples was used as reagent control.
Virus samples were diluted 1:4 in RNase free water. 1 μl
diluted sample was added to 19 μl reaction mixture con-
taining 250 μM of each dNTP, 2.5 ul of 10× PCR buffer
and 40 pmol of each forward and reverse primers. The
reaction mixture was first incubated at 95°C for 5 minutes
and then chilled on ice for 5 minutes. Once tube contacts
cooled, 5 μl mixture containing 2.0 mM MgCl2, 0.5 mM
DTT, 0.2 units Placental RNase inhibitor, 0.07 units AMV
reverse transcriptase and 1.5 units Taq polymerase was
added. The tubes were placed in thermocycler (BIORAD I-
cycler) and cycled as follows: 42°C for 20 min, 95°C for
3 min, 30 cycles at 95°C for 45 sec, 55°C for 45 sec 60°C
for 45 sec, respectively. 114 bp sized band of the PCR
amplified product was visualized under UV illumination
on 10% Poly-acrylamide gel after ethidium bromide
staining.
e) Data analysis




NPEV were isolated from 474 (26%) of a total of 1775
stool specimens collected during January 2003 to Septem-
ber 2003. The percentage of different virus isolates has
been summarized (Fig. 1).
A total of 398 (84%) NPEV isolates were reported from
children younger than 5 years. The detection of NPEV in
AFP cases decreased with the increase in age (Fig. 2) and
statistical analysis showed strong negative correlation (r =
-0.913) between age and detection of NPEV. The analysis
of the results by chi-square test showed high significance
(p = 0.002). Out of total 474 isolates, 276 (58%) were iso-
lated from males, with a male to female ratio of 1.4: 1. The
variation was not found significant (χ2 = 0.545 and p =
0.4602). Association between age and sex was checked by
applying chi square test and it was found that no associa-
tion existed between these two attributes (χ2 = 0.098 and
p = 0.99).
Virology
All the NPEV isolates were typed by micro-neutralization
assay. There were 220 (46%) Echoviruses, 63 (13%) Cox-
sackievirus B, 10 (2%) Coxsackievirus A9 and 181 (38%)
untypable viruses (Table 1). Echo-6 and Coxsackievirus B
were the most commonly isolated serotypes. The analysis
of the geographical distribution of the different serotypes
showed that NPEV serotypes are randomly distributed in
almost all parts of the country. All of 181 isolates found
untypable by microneutralization assay were amplified by
RT-PCR using pan-EV primers and all of these isolates
were confirmed as enteroviruses.
Clinical data
The case investigation forms of 190 NPEV-associated AFP
cases were analyzed for clinical characteristics. 116 (61%)
out of 190 patients were found to have fever at the onset
of paralysis. No correlation was found between age and
Enterovirus isolation rate from stool Figure 1




PV NPEVs NEVBMC Infectious Diseases 2007, 7:6 http://www.biomedcentral.com/1471-2334/7/6
Page 4 of 6
(page number not for citation purposes)
presence of fever (r = 0.02). The association between sex
and presence or absence of fever was statistically found
insignificant (χ2 = 0.4183, p = 0.5177). The paralysis was
found asymmetrical in 128 patients (67%). Legs were
affected in 95% patients while arms in 40%. The facial
palsy was observed only in 19 patients (10%). In 137
patients (72%) the paralysis progressed to peak within 4
days of onset, the progression took more than 4 days in 16
patients (8%) while no credible information could be
obtained for 37 patients (20%). The most common pre-
liminary diagnosis for AFP cases with NPEV isolates was
Guillain-Barre' syndrome (33%) followed by viral neu-
ropathy (Table 2). On 60 day follow up after the onset of
paralysis, residual paralysis was still present in 74 patients
(39%) while 23 patients (12%) died within 60 days fol-
lowing paralysis.
Discussion
The work presented here is the first report on prevalent
serotypes of NPEV in Pakistan along with their epidemiol-
ogy and clinical characteristics. The work also reflects that
isolation of NPEV from AFP cases is common in Pakistan.
The findings are in accordance with the studies conducted
in India, where NPEV were isolated from 34% of AFP
cases. The frequency of NPEV was higher because only the
children less than 4 year of age were recruited. Another
study in India had isolated NPEV from 20% of acute poli-
omyelitis cases [13,14].
Enteroviral infections are more prevalent in children than
in adults [29-31]. The age distribution of enterovirus-asso-
ciated illness in a 10-year surveillance report from the
United States recorded that most of the cases were
reported in young children [32]. The present study shows
that the age of children with NPEV-associated AFP ranged
from 1 to 14 years and that the isolation of NPEV
decreased significantly with the increase in age. Similar
pattern was observed by Morens who analyzed the reports
to the CDC on isolation of NPEV for the years 1971–1975
and found that the incidence of reported isolations
decreased with increasing age [31].
Serotyping of the NPEV isolated from the patients of AFP
in India showed that Echovirus 6, 11, 9 and coxsackievirus
B were the most frequent serotypes of NPEV [14]. In the
present study, 38% isolates could not be identified by the
antiserum pools provided by WHO. The pools contained
antibodies against only 21 of the 68 known human enter-
ovirus serotypes, so their failure to neutralize a given iso-
late could have been due to the absence of homologous
antibodies in the pools used, virus aggregation or pres-
ence of a virus mixture [15]. Many enterovirus isolates
could not be typed by the microneutralization test during
a study of epidemiology of different enterovirus serotypes
in Netherlands [33].
With worldwide Poliovirus surveillance and the recent
development of new molecular tools for enterovirus
Age wise distribution of NPEV isolates Figure 2
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Table 1: Identification of different serotypes identified by Microneutralization test
Serotype No. of Isolates Percentage of Total
ECHO 6 63 13
Cox B 63 13
ECHO 7 42 9
ECHO 13 35 7
ECHO 11 35 7
ECHO 4 14 3
Cox A9 10 2
ECHO 1 7 1
ECHO 25 7 1
ECHO 30 6 1
ECHO 20 6 1
ECHO 2 5 1
Untypable 181 38
Total 474 100BMC Infectious Diseases 2007, 7:6 http://www.biomedcentral.com/1471-2334/7/6
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detection and identification, more interest is being given
to NPEV especially in polio free countries. As the endemic
countries harbouring circulation of wild polioviruses also
happen to be developing countries therefore the utility of
resources remains low on research oriented activities. A
major chunk of resources is still being utilized for eradica-
tion activity in countries like Pakistan. Standard methods
for enterovirus detection and identification are based on
virus isolation on cell culture followed by serotyping the
isolated viruses by microneutralization assays using pools
of serotype specific antisera [34]. This procedure is time
consuming and labour intensive and the availability of
specific antisera gradually becomes restricted. Several
techniques for rapid detection of the enterovirus genome
in clinical samples, most of them based on PCR amplifi-
cation in the 5' non-coding (5' NC) of the genome have
been developed. In this study similar method was used to
identify the isolates (n = 181) that could not be serotyped
by enterovirus-specific pools available in the laboratory.
However such methods do not allow serotype identifica-
tion and genetic characterization of the detected viruses
beyond the genus level [35]. Thus when information on
the serotype is needed, virus isolation on cell culture
remains the most appropriate technique. To overcome the
problems related to the specific antisera, attempts have
been made to develop new methods for typing enterovi-
ruses by PCR amplification and partial sequencing in the
VP1 region of the genome [9-11].
Fever at the time of onset of paralysis is one of the cardinal
signs of poliomyelitis but cases of AFP with NPEV isolates
were also reported to have fever at the time of onset. Fever
was a major symptom in 53% AFP cases associated with
NPEV in India [14]. The presence of fever in almost two
third cases in the present study may be due to the fact that
most of the time case was reported from hospital where
the paralysis had reached its peak. The clinical significance
of fever at the onset of paralysis along with rapid progres-
sion of asymmetrical paralysis helps in the determination
of neuropathies caused by NPEV. 12% patients died
within 60 days of the onset of paralysis owing to the sever-
ity of disease. No association could be found out between
death of patient with age at infection or NPEV responsi-
ble.
'The progression of paralysis to peak within 4 days of
onset' was recorded in 52% of NPEV-associated AFP cases
in Americas with residual paralysis in 24% cases [16]. In
the present study, 'the progression of paralysis within 4
days of onset' demonstrated higher percentage reflecting
the high severity of disease but its association with low
immunity status or lack of proper treatment could not be
determined unless further studies are conducted.
Conclusion
The present study suggests that after the eradication of
poliomyelitis, AFP cases negative for wild poliovirus but
positive for NPEV will continue to be detected. The data
also confirms that NPEV circulation is common and iso-
lates may be obtained from persons with AFP whose clin-
ical findings do not resemble poliomyelitis. The results of
this study indicate that characterization of NPEV isolates
could provide better understanding of the epidemiology
of NPEV causing paralysis. Data generated from this study
will help future studies on NPEV serotypes circulating in
Pakistan and to formulate more effective strategies in view
of post eradication era. A better knowledge of the trans-
mission and the implications of NPEV in diseases may
also justify the future studies on their molecular epidemi-
ology.
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